Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Goodwill (2019 - 2025)

Lineage Cell Therapeutics' Goodwill history spans 7 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Goodwill changed 0.0% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, changed 0.0%, while the annual FY2025 figure was $10.7 million, 0.0% changed from the prior year.
  • Goodwill reached $10.7 million in Q4 2025 per LCTX's latest filing, roughly flat from $10.7 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $10.7 million in Q1 2021 to a low of $10.7 million in Q1 2021.
  • Average Goodwill over 5 years is $10.7 million, with a median of $10.7 million recorded in 2021.
  • The largest YoY upside for Goodwill was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
  • A 5-year view of Goodwill shows it stood at $10.7 million in 2021, then changed by 0.0% to $10.7 million in 2022, then changed by 0.0% to $10.7 million in 2023, then changed by 0.0% to $10.7 million in 2024, then changed by 0.0% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Goodwill are $10.7 million (Q4 2025), $10.7 million (Q3 2025), and $10.7 million (Q2 2025).